Critical Care Medicine
Gastrointestinal Emergencies: Necrotizing Enterocolitis (NEC)
Necrotizing Enterocolitis (NEC)
1. Description of the problem
NEC is characterized by ischemia and necrosis of the gastrointestinal tract and can lead to mortality and morbidity, including short bowel syndrome. It is most often found in premature infants and requires early recognition and treatment to prevent long segment bowel necrosis.
Most infants diagnosed with NEC are premature but are relatively healthy and feeding well prior to the development of NEC.
Signs of sepsis
Lack of bowel sounds
Key management points
Early Identification - pneumatosis intestinalis and ileus on AXR
Early Treatment - antibiotics, cessation of oral feeding, possible surgical exploration
Serial abdominal X-rays
The mainstay of NEC diagnosis remains abdominal radiography, although abdominal ultrasound may have some utility, especially with ultrasound expertise.
AXR - dilated bowel loops, ileus, pneumatosis intestinalis, pneumoperitoneum, fixed loops
While the diagnosis of NEC relies on radiographic evidence, laboratory evaluation may further suggest NEC. These findings include:
Low neutrophil count
4. Specific Treatment
Fluid resuscitation and replacement of insensible losses
Bowel rest with NG suction
Total parenteral nutrition
Antibiotic coverage (see below)
Laparotomy with resection of necrotic bowel and peritoneal drain placement
Drugs and dosages
Vancomycin, gentamicin, and clindamycin or metronidazole or piperacillin-tazobactam.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
- Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL